Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus

Area of Science:

• Neuroscience
• Cardiovascular Medicine
• Endocrinology

Background:

• Type 2 diabetes mellitus (T2DM) is linked to microvascular dysfunction, potentially increasing dementia risk.
• Resveratrol has shown promise in improving systemic circulation vasodilator function.
• Cerebral blood flow regulation may be compromised in T2DM, impacting cognitive function.

Purpose of the Study:

• To investigate the dose-dependent effects of resveratrol on cerebral vasodilator responsiveness (CVR) in T2DM.
• To determine the most efficacious dose of resveratrol for improving CVR in the cerebral vasculature.
• To assess the potential of resveratrol to mitigate microvascular dysfunction in T2DM.

Main Methods:

• A double-blind, placebo-controlled, crossover study involving 36 T2DM adults.
• Administration of single doses of synthetic trans-resveratrol (0, 75, 150, 300 mg) at weekly intervals.
• Assessment of CVR using transcranial Doppler ultrasound during hypercapnic challenge, measuring flow velocity in middle and posterior cerebral arteries.

Main Results:

• Resveratrol significantly increased CVR in the middle cerebral arteries (MCA) across multiple doses (75, 150, 300 mg).
• The 75 mg dose of resveratrol was found to be efficacious in improving CVR in the posterior cerebral arteries (PCA).
• Maximum improvement in CVR was observed with the lowest dose of resveratrol tested (75 mg).

Conclusions:

• This study provides the first clinical evidence of resveratrol acutely enhancing cerebral vasodilator responsiveness in T2DM.
• Resveratrol may offer a therapeutic strategy to address endothelial dysfunction and sub-clinical cognitive impairment associated with T2DM.
• The findings suggest that lower doses of resveratrol may be sufficient to elicit beneficial effects on cerebral circulation in T2DM patients.